Press Releases Events & Presentations Events & Presentations Featured Events May 27 - May 30, 2026 European Association for the Study of the Liver (EASL) Congress 2026 Supporting Materials Safety, Pharmacokinetics, and Pharmacodynamic Activity of ABI-6250, a First-in-Class Oral Hepatitis D Virus Entry Inhibitor in Healthy Subjects: Interim Results From a Randomized, Blinded, Phase 1a Study 375.2 KB Upcoming Events Jun 3, 2026 at 4:20 PM EDT Jefferies 2026 Global Healthcare Conference - Fireside Chat Listen to webcast Add to Outlook Add to Google Calendar Jun 8, 2026 at 8:40 AM EDT Goldman Sachs Global Conference Listen to webcast Add to Outlook Add to Google Calendar Presentations Assembly Biosciences Corporate Presentation Shareholder Tools Print Email Alerts RSS News Feeds Search Investors
Events & Presentations Featured Events May 27 - May 30, 2026 European Association for the Study of the Liver (EASL) Congress 2026 Supporting Materials Safety, Pharmacokinetics, and Pharmacodynamic Activity of ABI-6250, a First-in-Class Oral Hepatitis D Virus Entry Inhibitor in Healthy Subjects: Interim Results From a Randomized, Blinded, Phase 1a Study 375.2 KB Upcoming Events Jun 3, 2026 at 4:20 PM EDT Jefferies 2026 Global Healthcare Conference - Fireside Chat Listen to webcast Add to Outlook Add to Google Calendar Jun 8, 2026 at 8:40 AM EDT Goldman Sachs Global Conference Listen to webcast Add to Outlook Add to Google Calendar Presentations Assembly Biosciences Corporate Presentation
Safety, Pharmacokinetics, and Pharmacodynamic Activity of ABI-6250, a First-in-Class Oral Hepatitis D Virus Entry Inhibitor in Healthy Subjects: Interim Results From a Randomized, Blinded, Phase 1a Study 375.2 KB
